<DOC>
	<DOCNO>NCT00243412</DOCNO>
	<brief_summary>This Phase II , randomize , double-blind , multicenter study design evaluate safety efficacy rituximab , administer two different regimen 2 year , patient moderate severe active rheumatoid arthritis ( RA ) receive stable dos methotrexate ( MTX ) .</brief_summary>
	<brief_title>A Study Safety Efficacy Rituximab Patients With Moderate Severe Rheumatoid Arthritis Receiving Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Diagnosis RA least 6 month . Inadequate response MTX Use folate If female childbearing potential , negative serum pregnancy test within 8 week prior first rituximab infusion Diagnosis juvenile idiopathic arthritis ( also know juvenile rheumatoid arthritis ) and/or RA age 16 Any surgical procedure , include bone/joint surgery plan surgery within 8 week prior screen within 16 week Week 1 ( Day 1 ) visit Inflammatory arthritis RA ( e.g. , inflammatory bowel disease , systemic lupus erythematosus ( SLE ) , psoriatic arthritis ) Functional Class IV define American College Rheumatology ( ACR ) classification functional status RA Use diseasemodifying antirheumatic drug ( DMARDs ) MTX within 4 week prior randomization ( 8 week prior infliximab , adalimumab , leflunomide ) Treatment investigational agent within 4 week screen 5 halflives investigational drug ( whichever longer ) Previous treatment Tysabri &lt; TM &gt; ( natalizumab ) Previous treatment rituximab Previous treatment celldepleting therapy , include investigational agent Treatment IV &amp; globulin Prosorba ( R ) Column within previous 6 month Use intraarticular parenteral corticosteroid within 4 week prior screen visit Receipt vaccine within 4 week prior Day 1 infusion History severe allergic anaphylactic reaction humanize murine monoclonal antibody Primary secondary immunodeficiency ( history active ) Evidence significant uncontrolled concomitant diseases cardiovascular disease , nervous system , renal , hepatic , endocrine , gastrointestinal , pulmonary disease , include pulmonary condition would preclude subject participation ensue 2 year Known active bacterial , viral , fungal , mycobacterial , infection ( include tuberculosis atypical mycobacterial disease , exclude fungal infection nail bed ) History recurrent significant infection significant episode infection require hospitalization treatment IV antibiotic within 4 week screen oral antibiotic within 2 week prior screen History significant cytopenia bone marrow disorder History cancer , include solid tumor hematologic malignancy ( except basal cell squamous cell carcinoma skin excise cure ) Pregnant nursing ( breast feed ) woman Lack peripheral venous access Chronic daily use narcotic analgesic History alcohol , drug , chemical abuse within 6 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Rituxan</keyword>
	<keyword>RA</keyword>
</DOC>